Mono Pharmacare Limited — Results, 06-01-2025: Reply to Clarification- Financial results

For the period ending September 30, 2024, Mono Pharmacare Limited reported a total funds utilization of ₹1,370.16 crore against a projected utilization of ₹1,484 crore as per their prospectus. This shows an effective usage of capital, with about ₹113.84 crore still pending for utilization.

The funds were categorized primarily as follows: ₹898 crore allocated for working capital requirements has been fully utilized, while ₹366 crore earmarked for general corporate purposes saw ₹252.16 crore utilized, leaving ₹113.84 crore pending. Additionally, ₹220 crore set aside for issue expenses was fully utilized.

The data indicates solid execution on the capital allocation front, particularly in working capital management. However, the pending amount for general corporate purposes suggests possible delays or strategic re-evaluations within that category. Overall, the financial health appears stable with significant transparency in fund allocation, reflecting on investor sentiment positively.

Given these insights, it may be prudent to maintain a hold position as the company refines its utilization strategy, weighing potential growth opportunities against current allocations.